GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » 12-1 Month Momentum %

Clearmind Medicine (Clearmind Medicine) 12-1 Month Momentum % : -93.39% (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-22), Clearmind Medicine's 12-1 Month Momentum % is -93.39%.

The industry rank for Clearmind Medicine's 12-1 Month Momentum % or its related term are showing as below:

CMND's 12-1 Month Momentum % is ranked worse than
96.02% of 1482 companies
in the Biotechnology industry
Industry Median: -26.745 vs CMND: -93.39

Competitive Comparison of Clearmind Medicine's 12-1 Month Momentum %

For the Biotechnology subindustry, Clearmind Medicine's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's 12-1 Month Momentum % falls into.



Clearmind Medicine  (NAS:CMND) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clearmind Medicine  (NAS:CMND) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Clearmind Medicine 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine (Clearmind Medicine) Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind Medicine (Clearmind Medicine) Headlines

From GuruFocus